The Less is More Study

NCT ID: NCT05153811

Last Updated: 2025-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-10

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this project, the investigators will implement innovations to extend use of Contingency Management (CM) to facilitate alcohol use reduction among people living with HIV (PLWH). The investigators' approach to extending CM will use mobile health (mHealth) tools including a smartphone breathalyzer device with accompanying app and a wrist worn alcohol biosensor. Participants will be engaged in mobile facilitated CM for 30-60 days with follow-up out to 6 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-Contingent Condition

Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, encouragement to reduce drinking but payment not based on drinking.

Group Type EXPERIMENTAL

Counseling

Intervention Type BEHAVIORAL

Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.

mHealth and CM

Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings. Participants will also interact with a mobile health application to facilitate drinking reduction.

Group Type EXPERIMENTAL

Counseling

Intervention Type BEHAVIORAL

Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning

mHealth

Intervention Type BEHAVIORAL

Participants will engage with an application designed to gamify drinking reduction.

CM

Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings

Group Type EXPERIMENTAL

Counseling

Intervention Type BEHAVIORAL

Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Counseling

Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning

Intervention Type BEHAVIORAL

mHealth

Participants will engage with an application designed to gamify drinking reduction.

Intervention Type BEHAVIORAL

Counseling

Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Frequent alcohol use in the past 30 days based on responses on the Timeline Followback (TLFB; Sobell and Sobell, 2003)
* HIV positive
* Fluency in English
* Willingness to attempt alcohol abstinence for at least 30 days and then to attempt alcohol use on fewer days than at baseline after that
* Willingness to use smartphone applications and biosensor devices (i.e., breathalyzer device and wrist sensor) for alcohol use reduction purposes in the study. If participants do not have a compatible smartphone to use, they will be loaned one by the study

Exclusion Criteria

* Psychiatric conditions that would interfere with participation in the study
* Current alcohol withdrawal as indicated by a score of 8 or higher on the Clinical Institute Withdrawal Scale (CIWA; Sullivan et al., 1989) or lifetime history of medically assisted detoxification
* Two positive breath alcohol concentration (BrAC) readings (i.e., \> 0.00%) at an in-person screening appointment. After participants blow their first positive BrAC, they will be allowed to reschedule and participate at another time, however if they blow a second positive BrAC, they will be excluded from this study and offered referrals for alcohol treatment.
* Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
* Psychosis or other severe psychiatric disability
* Pregnancy, nursing or lack of reliable birth control use for women who have not yet reached menopause
Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Miami

OTHER

Sponsor Role collaborator

University of Louisville

OTHER

Sponsor Role collaborator

Florida State University

OTHER

Sponsor Role collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

Sponsor Role collaborator

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Leeman, Ph.D

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Miami

Coral Gables, Florida, United States

Site Status RECRUITING

University of Florida

Gainesville, Florida, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emmely Pavila

Role: CONTACT

352-273-9562

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Varan Govind, PhD

Role: primary

305-243-8096

Emmely Pavila, B.A., B.S.

Role: primary

352-273-9562

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P01AA029543

Identifier Type: NIH

Identifier Source: secondary_id

View Link

PRO00035889

Identifier Type: OTHER

Identifier Source: secondary_id

OCR41499

Identifier Type: OTHER

Identifier Source: secondary_id

CED000000577

Identifier Type: OTHER

Identifier Source: secondary_id

CED000000577

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Selective Exposure in HIV Prevention
NCT01152281 COMPLETED PHASE2